2026– date –
-
TSMC Accelerates CoWoS and SoIC Expansion to Quell AI Chip Bottleneck, Targets 4x Capacity by 2026
FinancialContent - Stock Market Taiwan Overview TSMC is aggressively expanding its CoWoS and SoIC advanced packaging capacity to address the soaring demand for AI chips, aiming to increase monthly wafer output from approximately 35,000 u... -
EV Group Unlocks Next-Gen Semiconductor Performance with Advanced Integration Technologies at ECTC 2026
EV Group オーストリア Overview At ECTC 2026, EV Group showcased its latest advancements in hybrid bonding, layer transfer, and maskless lithography, offering crucial solutions for next-generation heterogeneous integration and advanced pa... -
Amkor Technology Secures CHIPS Act Funding, Expands U.S. Advanced Packaging Footprint in Arizona
Amkor Technology (via Business Wire) USA Overview Amkor Technology is significantly boosting its U.S. advanced packaging and test capabilities by acquiring an additional 67 acres adjacent to its existing 104-acre campus in Peoria, Arizon... -
Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors
FirstWord Pharma China Overview Shanghai Henlius Biotech, Inc. announced that its self-developed c-Met/EGFR bispecific antibody-drug conjugate (ADC), HLX48, has received Investigational New Drug (IND) approval from China's National Medic... -
Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies
The Elec Inc. South Korea Overview The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly's Retatrutide, a triple agonist for GLP-1, GIP, and gl... -
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli... -
BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor
Stock Titan USA Overview BeOne Medicines announced that BEQALZI™ (sonrotoclax) has received U.S. FDA approval for the treatment of relapsed/refractory Mantle Cell Lymphoma (MCL), marking it as the first BCL2 inhibitor for this indication... -
GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation
GSK USA Overview GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA.... -
Incyte Partners with Edison Scientific to Integrate “Kosmos” AI Platform for Enhanced Drug Discovery and Development
Investing.com Canada USA Overview Incyte has announced a partnership with Edison Scientific to integrate Edison's AI platform, "Kosmos," into its drug discovery and development processes. This collaboration focuses on target discovery, v... -
GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment
DDN Magazine USA Overview This week's DDN Weekly Rundown reports that GLP-1 gene therapy has advanced into its first human clinical trials, alongside the potential emergence of the first disease-modifying therapy for endometriosis. The e...
